达安基因(002030) - 2024 Q2 - 季度业绩预告

Financial Performance - The net profit attributable to shareholders is expected to be a loss of between 350 million and 430 million CNY, compared to a profit of 402.76 million CNY in the same period last year[6]. - The net profit after deducting non-recurring gains and losses is expected to be a loss of between 130 million and 180 million CNY, compared to a loss of 36.31 million CNY in the same period last year[6]. - Basic earnings per share are expected to be a loss of between 0.25 CNY and 0.31 CNY per share, compared to earnings of 0.29 CNY per share in the same period last year[6]. - The decrease in net profit is primarily due to reduced market demand and adjustments in centralized procurement prices, leading to a decrease in operating revenue[12]. - The fair value change of other non-current financial assets is expected to negatively impact the net profit attributable to shareholders by approximately 250 million CNY, classified as non-recurring gains and losses[8]. Reporting and Compliance - The financial data presented is preliminary and has not been audited by an external auditor, with detailed financial data to be disclosed in the company's 2024 semi-annual report[13]. - The performance forecast period is from January 1, 2024, to June 30, 2024[5]. - The company emphasizes the importance of accurate information disclosure and urges investors to make cautious decisions[4]. - The performance forecast is based on preliminary calculations by the company's finance department[11]. - The company will comply with relevant laws and regulations regarding timely information disclosure[13].